An example of a combinational therapy involving existing drugs is the use of JAK/HDAC inhibitors, which have already been employed in haematological malignancies, presenting a prospective therapeutic target for CTCL. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.